SOPHiA GENETICS (NASDAQ:SOPH) Insider Sells $24,100.00 in Stock

Key Points

• Insider Philippe Menu sold 5,000 shares on April 27 at an average price of $4.82 under a pre-arranged Rule 10b5-1 plan, generating $24,100 and adding to a string of sales earlier in April.
• Following the transaction Menu directly owns 261,388 shares, a 1.88% reduction in his stake.
• SOPH shares traded up to $5.04 (up 3.6%); the company reported a negative EPS of $0.28 last quarter, has a market cap of about $345 million, and carries an average analyst price target near $7.50 (consensus rating: Hold).

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) insider Philippe Menu sold 5,000 shares of the company's stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $4.82, for a total value of $24,100.00. Following the transaction, the insider directly owned 261,388 shares of the company's stock, valued at $1,259,890.16. This represents a 1.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Philippe Menu also recently made the following trade(s):

• On Monday, April 20th, Philippe Menu sold 608 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.20, for a total value of $3,161.60.
• On Tuesday, April 14th, Philippe Menu sold 1,600 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.96, for a total value of $7,936.00.
• On Monday, April 13th, Philippe Menu sold 4,400 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.76, for a total value of $20,944.00.
• On Friday, April 10th, Philippe Menu sold 3,725 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.68, for a total value of $17,433.00.
• On Thursday, April 9th, Philippe Menu sold 1,931 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.74, for a total transaction of $9,152.94.
• On Wednesday, April 8th, Philippe Menu sold 2,800 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.84, for a total transaction of $13,552.00.
• On Tuesday, April 7th, Philippe Menu sold 2,400 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.87, for a total transaction of $11,688.00.
• On Monday, April 6th, Philippe Menu sold 2,700 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.85, for a total transaction of $13,095.00.
• On Thursday, March 19th, Philippe Menu sold 608 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.79, for a total transaction of $2,912.32.

SOPHiA GENETICS Stock Up 3.6%

NASDAQ:SOPH traded up $0.18 on Tuesday, hitting $5.04. 67,187 shares of the company's stock were exchanged, compared to its average volume of 172,666. The firm has a 50-day moving average price of $4.79 and a 200-day moving average price of $4.76. SOPHiA GENETICS SA has a 52 week low of $2.59 and a 52 week high of $5.70. The company has a debt-to-equity ratio of 1.01, a current ratio of 1.96 and a quick ratio of 1.84. The company has a market cap of $344.85 million, a P/E ratio of -9.87 and a beta of 1.04.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last announced its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.08). SOPHiA GENETICS had a negative net margin of 44.22% and a negative return on equity of 50.60%. The company had revenue of $21.71 million during the quarter, compared to the consensus estimate of $21.20 million.

Institutional Trading of SOPHiA GENETICS

Hedge funds have recently made changes to their positions in the business. First Dallas Securities Inc. acquired a new position in shares of SOPHiA GENETICS during the 1st quarter worth approximately $50,000. 1492 Capital Management LLC lifted its holdings in SOPHiA GENETICS by 8.4% during the 1st quarter. 1492 Capital Management LLC now owns 225,751 shares of the company's stock valued at $1,117,000 after purchasing an additional 17,406 shares during the last quarter. Silverberg Bernstein Capital Management LLC lifted its holdings in SOPHiA GENETICS by 8.7% during the 1st quarter. Silverberg Bernstein Capital Management LLC now owns 51,970 shares of the company's stock valued at $257,000 after purchasing an additional 4,155 shares during the last quarter. XTX Topco Ltd bought a new position in SOPHiA GENETICS during the fourth quarter worth $55,000. Finally, Quadrature Capital Ltd acquired a new position in shares of SOPHiA GENETICS in the fourth quarter valued at $54,000. 31.59% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

SOPH has been the subject of several recent analyst reports. Weiss Ratings reissued a "sell (d-)" rating on shares of SOPHiA GENETICS in a report on Tuesday, April 21st. Guggenheim upped their price target on shares of SOPHiA GENETICS from $6.00 to $7.00 and gave the stock a "buy" rating in a research report on Monday, January 26th. Finally, BTIG Research increased their price target on shares of SOPHiA GENETICS from $7.00 to $8.00 and gave the company a "buy" rating in a research note on Wednesday, April 15th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average price target of $7.50.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.